Common Contracts
4 similar Underwriting Agreement contracts by Idenix Pharmaceuticals Inc, Longboard Pharmaceuticals, Inc., Radian Group Inc, Zogenix, Inc.
Longboard Pharmaceuticals, Inc. [•] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • March 8th, 2021 • Longboard Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
ZOGENIX, INC. 4,750,000 Shares Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 30th, 2015 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Leerink and Stifel are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 4,750,000 shares (the “Initial Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of the 712,500 addi
RADIAN GROUP INC. (a Delaware corporation)Underwriting Agreement • May 13th, 2014 • Radian Group Inc • Surety insurance • New York
Radian Group Inc., a Delaware corporation (the “Company”), confirms its agreement with Goldman, Sachs & Co. (“Goldman Sachs”) and each of the other Underwriters names in Schedule A hereto (collectively, the “Underwriters”, which term shall also include any underwriter substituted as hereinafter provided in Section 12 hereof), for whom Goldman Sachs is acting as representative (in such capacity, the “Representative”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $300,000,000 aggregate principal amount of the Company’s 5.500% Senior Notes due 2019 (the “Securities”). The Securities are to be issued pursuant to the provisions of a Senior Indenture, dated as of March 4, 2013 (the “Base Indenture”), as supplemented by the Second Supplemental Indenture, to be dated as of May 13, 2014 (the “Supplemental Indenture”, and together with the Base Indenture, the “In
IDENIX PHARMACEUTICALS, INC. (a Delaware corporation) 6,460,672 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 30th, 2010 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations • New York
Thomas Weisel Partners LLC as representative of the Underwriters named in Schedule A hereto, c/o Thomas Weisel Partners LLC One Montgomery Street, Suite 3700 San Francisco, CA 94104
